Freeline Presents on Its Fabry and Gaucher Disease AAV-Based Gene Therapies at the 18th Annual WORLDSymposium™
February 08, 2022 07:00 ET
|
Freeline Therapeutics
FLT190 well-tolerated with promising early efficacy in Fabry disease including sustained α-Gal A expression up to two years GALILEO-1, a first-in-human, open-label, international, multicenter Phase...
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 03, 2022 16:01 ET
|
Freeline Therapeutics
LONDON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
Freeline Appoints Henning R. Stennicke, PhD, as Chief Scientific Officer to Lead Research and Discovery
February 03, 2022 07:00 ET
|
Freeline Therapeutics
LONDON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
Freeline to Present on Its Fabry and Gaucher Disease AAV-Based Gene Therapies at the 18th Annual WORLDSymposium™
January 27, 2022 16:01 ET
|
Freeline Therapeutics
LONDON, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
EHang Receives Pre-order for 50 Units of EH216 in Japan
January 20, 2022 08:00 ET
|
EHang Holdings Limited
GUANGZHOU, China, Jan. 20, 2022 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world's leading autonomous aerial vehicle (“AAV”) technology platform company,...
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 06, 2022 16:01 ET
|
Freeline Therapeutics
LONDON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
Freeline Announces FDA Clearance of Investigational New Drug Application for FLT201 for Gaucher Disease Type 1
January 06, 2022 07:00 ET
|
Freeline Therapeutics
FLT201 is the first AAV gene therapy program to enter the clinic for Gaucher disease Type 1 FLT201 Phase 1/2 trial for Gaucher disease Type 1 on track for patient dosing in the first half of 2022 ...
Freeline To Participate In Conferences During January 2022
January 04, 2022 16:01 ET
|
Freeline Therapeutics
LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the "Company" or "Freeline"), a clinical-stage biotechnology company developing transformative...
EHang Launches 5G Intelligent Air Mobility Experience Center as AAV Operation Spot in Guangzhou
December 29, 2021 08:04 ET
|
EHang Holdings Limited
The 5G Intelligent Air Mobility Experience Center launches in Guangzhou as a new operation spot under EHang’s 100 Air Mobility Routes Initiative. EHang and Guangzhou Development District...
Freeline Announces 2022 Corporate Priorities and Guidance
December 13, 2021 17:40 ET
|
Freeline Therapeutics
Promising execution in the clinic with programs in hemophilia B, Fabry disease and Gaucher disease; potential to deliver transformative therapies driven by Freeline’s differentiated platform Data...